Tolvaptan slows disease progression in late-stage ADPKD
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
http://www.nature.com/articles/nrneph.2017.180.pdf
Reference10 articles.
1. Ong, A. C., Devuyst, O., Knebelmann, B., Walz, G. & ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993–2002 (2015).
2. Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 86, 1244–1252 (2014).
3. Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930–1942 (2017).
4. Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
5. Mao, Z., Chong, J. & Ong, A. C. Autosomal dominant polycystic kidney disease: recent advances in clinical management. F1000Res 5, 2029 (2016).
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD;Nephrology Dialysis Transplantation;2024-01-15
2. Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't;Clinical Kidney Journal;2022-04-21
3. Patient-derived cellular models of primary ciliopathies;Journal of Medical Genetics;2022-02-19
4. An update on the use of tolvaptan for ADPKD: Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders (WGIKD), the European Rare Kidney Disease Reference Network (ERKNet) and Polycystic Kidney Disease International (PKD-International);Nephrology Dialysis Transplantation;2021-11-19
5. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis;Pharmacological Research;2020-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3